The study of the pathogenesis of 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary carcinomas has led to an understanding of the mechanisms controlling tumour initiation and of the role played by mammary gland differentiation (Russo et al., 1977 (Russo et al., , 1978 (Russo et al., , 1979 (Russo et al., , 1980 (Russo et al., , 1987a . The mammary gland of Sprague-Dawley rats exhibits the highest susceptibility to malignant transformation when the carcinogen affects undifferentiated terminal ductal structures or terminal end buds (TEBs) which are present in the immature gland of young virgin animals (Russo et al., 1977 (Russo et al., , 1987a . The susceptibility of the mammary gland to neoplastic transformation decreases progressively with ageing and more markedly with differentiation, such as that occurring after full-term pregnancy (Dao et al., 1960; Grubbs et al., 1983a Grubbs et al., , 1986 Moore et al., 1981; Russo et al., 1978 Russo et al., , 1979 Russo et al., , 1980 Russo et al., , 1987a . An additional factor influencing the susceptibility of the mammary gland to carcinogenesis is the asynchronous development of mammary glands located in different topographic locations. Mammary glands located in the thoracic region develop a greater number of tumours than those located in the abdominal or inguinal regions (Gullino et al., 1975; Moore et al., 1981; Russo et al., 1987a) , what is attributed to a delayed differentiation of thoracic mammary glands (Russo et al., 1987a) .
Although it is known that both mammary differentiation and tumorigenesis are modulated by hormones, and that a majority of chemically-induced mammary cancers are hormone dependent, since they can be suppressed by either hormone deprivation, hormone administration, or by pregnancy and lactation (Dao et al., 1960; Grubbs et al., 1983a Grubbs et al., , b, 1986 Huggins et al., 1961; McCormick et al., 1973; Moore et al., 1981; Nicholson et al., 1988; Russo & Russo, 1986 Welsch, 1985) , the definitive role of hormones in tumour progression still remains to be elucidated. mammary gland from neoplastic transformation (Dao et al., 1960; Russo et al., 1980 Russo et al., , 1987a , whereas pregnancy initiated after carcinogen administration has been reported to shorten the latency period, to accelerate the growth of mammary cancer and to increase the number of active centres (Huggins et al., 1962) . Dao et al. (1960) also reported shortened latency period in tumour development during pregnancy and increased short term tumour incidence, but decreased overall tumorigenic response, whereas Moore et al. (1981) and Grubbs et al. (1986) found pregnancy to be protective. It has been shown that the protective effect of pregnancy prior to carcinogen administration is due to induction of differentiation of the mammary gland (Russo et al., 1978 (Russo et al., , 1980 , however, the exact mechanism of action of each specific hormone prior to or after carcinogen administration is not known. It has not been clarified what hormonal levels or what hormone combinations determine the protective degree of gland development induced by pregnancy. Although most attempts to stimulate mammary development have utilised ovarian hormones, pituitary hormones, or synthetic agents (Dao et al., 1960; Huggins et al., 1962; McCormick et al., 1973; Welsch, 1985) the role of the most abundant placental hormone, chorionic gonadotropin, on mammary gland differentiation has not been explored. Chorionic gonadotropin, a polypeptide hormone produced by the placenta is composed of an alpha and a beta subunit. The alpha subunit is identical to that of the pituitary gonadotropins luteinizing hormone (LH), follicle stimulating hormone (FSH) and thyroid stimulating hormone (TSH). The beta subunits of these hormones differ in amino acid sequence (Segal, 1980) . The action of chorionic gonadotropin is identical to that of LH and has some small degree of FSH activity, stimulating production of progesterone by the ovary.
We have determined that treatment of intact virgin rats with chorionic gonadotropin affects the mammary gland structure, cell kinetics and level of cell differentiation (Russo, 1983) . HCG mimics the physiological effect of pregnancy, since treatment of virgin rats with 10-1OOIU for 21 days prevents the initiation of mammary cancer through induction of long-lasting structural changes in the mammary gland, namely a greater lobular formation, with concomitant reduction in the number of TEBs and in the rate of cell proliferation of the mammary epithelium (Russo, 1983) .
These data indicate that mammary gland differentiation prior to exposure to a carcinogen by means other than pregnancy is a reasonable approach for mammary cancer prevention (Russo et al., 1987a (Russo et al., , 1988 Russo, 1983; Tay et al., 1985) . In devising strategies for hormone prevention of mammary carcinogenesis in the human population, however, it is important to bear in mind an important difference between the human and the experimental conditions; in experimental animals the time and site of appearance of mammary lesions have been identified (Russo et al., 1977) whereas in the human population the site of origin has been postulated (Russo et al., 1987b (Russo et al., , 1990 In order to assess the role of hCG on the progression of DMBA mammary carcinomas, fifty day-old virgin rats were divided into two groups: group I animals received a single intragastric dose of 8 mg DMBA per 100 g body weight (Eastman Organic Chemicals, Rochester, NY). DMBA was dissolved in corn oil heated in a water bath at 100°C for 15 min. After carcinogen administration, the animals remained undisturbed, except for bi-weekly palpation for detection of tumour development. Group II animals were administered DMBA at age 50, as group I animals, but starting 21 days after carcinogen administration, time at which intraductal proliferations have been reported to be already present (Russo et al., 1977) , they received one daily intraperitoneal (i.p.) injection of 100 IU chorionic gonadotropin (hCG) (Sigma Chemical Company, St Louis, MO) for 60 days. All the animals were weighed at the beginning of the experiment, and at 16 weeks post-treatment. Weights determined at the end of the experiment were not utilised to avoid the influence of tumour burden, mainly in group I animals. All the animals were palpated twice a week for detection of tumour development. Date of tumour appearance, tumour location and tumour size, which was measured in two dimensions with a vernier caliper, were recorded. All the animals were killed 24 weeks post-DMBA administration. All tumours and the mammary glands were dissected from the skin and processed as described elsewhere (Russo et al., 1989a) . Sections of tumours were stained with hematoxylin and eosin and tumours were classified by applying criteria published elsewhere (Russo et al., 1989b,c (Zar, 1984) . (Table I) . No histological abnormalities were noted in these organs as a consequence of treatment. HCG treatment induced a significant increase (P<0.01) in ovarian weight over the weight of controls. The maximal increase occurred at the end of treatment, decreasing thereafter; although the ovarian weight of treated animals remained at a higher value than in virgin controls, the difference was not significant. The increase in weight was due to an increase in number and size of corpora lutea, which were histologically normal. No significant differences in uterine weight were observed between treated and virgin control animals ( Table I ).
Effect of hCG on DMBA-induced mammary carcinogenesis All group I animals developed mammary tumours (Table II , Figure 1 ), a total of 121 tumours, 60.3% located in the thoracic region and 39.7% in the abdominal region (Tables  III and IV (Table IV) . The number of tumours per animal was markedly reduced, since the average number of tumours per animal per number of animals with tumours was 1.8 and the number of tumours per animal per number of animals at risk was 0.9 (Table II) . Tumours became palpable as early as 49 days post-carcinogen administration in both groups. The time of tumour appearance ranged from 49 to 154 days, with no statistical differences between control and experimental groups (Table II) . Many tumours were not palpable and were first detected at the time of autopsy. When the tumours were histologically classified, it was found that in group I animals, 93 out of 121 tumours (76.8%) were adenocarcinomas (Table IV) ; they developed in 100% of the animals, with an average of 3.1 adenocarcinomas per animal (Table II) ; 64.5% of adenocarcinomas were located in the thoracic region and 35.5% in the abdominal region. Adenocarcinoma incidence was markedly reduced in group II animals. Of a total of 31 tumours developed 26 were adenocarcinomas, which were present in only 45.5% of the animals ( Table II) . The number of carcinomas per animal was reduced to 1.7 adenocarcinomas per animal per number of animals with tumours, or 0.8 tumours per animal per number of animals at risk (Table II) ; 73% of the adenocarcinomas were located in the thoracic region, and 27% in the abdominal region. The incidence of adenocarcinomas in group II was significantly lower than in group I animals (Table II) . Although the percentage of adenocarcinomas was substantially higher in thoracic than in abdominal mammary glands, tumour distribution was similar in groups I and II animals, as shown by the x2 test. Benign lesions, which consisted exclusively of fibroadenomas, represented 23.2% and 16.1% of the total number of lesions in groups I and II animals respectively. Their distribution did not differ significantly between the two topographic regions (Table IV) .
Discussion
Results presented here demonstrate that human chorionic gonadotropin (hCG) treatment of virgin Sprague-Dawley rats in which mammary carcinomas have been initiated by administration of DMBA are significantly protected from tumour development.
The choice of hCG treatment was based upon the observation that full-term pregnancy-induced gland differentiation occurring before carcinogen administration is a protective factor in chemically induced mammary gland carcinogenesis (Russo, 1983; Russo et al., 1978 Russo et al., , 1980 Russo et al., , 1987a ; this observation suggested to us that placental hormones play an important role in both mammary development and protection from neoplastic transformation.
Chorionic gonadotropin (CG) produced by the placenta of rats, mice and hamsters is structurally similar to human CG (Wide et al., 1980) . In rodents, significant amounts of CG have been detected in extracts of implantation sites of placentae throughout the period of gestation, with a maximum level detected between days 11 and 13 (Wide et al., 1980) . The protective effect of hCG on mammary carcinogenesis was first reported in 1983 (Russo, 1983) . Doses of 10 or. 100 IU applied daily for 21 days were found to be protective even when treatment was terminated 21 days prior to carcinogen exposure (Russo, 1983; Russo et al., 1987a) . HCG administered at these doses is not tumorigenic per se and does not induce alterations in body weight or in the weight of endocrine organs such as pituitary gland, ovaries and adrenal gland. It induces alterations in the oestrous cycle during the time of administration, but this effect reverts upon discontinuation of hormone administration.
Results reported here demonstrate that pharmacological doses of hCG administered 21 days after the carcinogen produce significant reduction in the number of tumours and of adenocarcinomas developed, even though tumour initiation has already taken place (Russo et al., 1977) . Tumour development was constantly depressed throughout the injection period and thereafter, what indicates that the inhibitory effect of the hormone is persistent and probably due to structural alterations of the mammary gland. The observation that thoracic mammary glands retain their greater susceptibility to neoplastic transformation even after the hormonal treatment indicates that hCG affects equally mammary glands located in different topographic areas without altering intrinsic properties of the mammary epithelium involved in this process.
The comparison of the effect of hCG treatment with that of pregnancy is straightforward with results reported by Grubbs et al. (1983a Grubbs et al. ( , 1986 and Moore et al. (1981) , who found a protective effect when pregnancy was initiated soon after carcinogen administration. Dao et al. (1960) also reported complete inhibition of tumorigenesis when pregnancy was initiated simultaneously with carcinogen administration, and reduced overall tumour incidence when pregnancy was initiated at a later date, although these authors report decreased latency period and greater short term tumour incidence. Huggins et al. (1962) , on the other hand, reported shortened latency period and greater overall tumour incidence when pregnancy was initiated 15 days post-DMBA administration. The period of time between carcinogen administration and hormonal stimulation seems to be the most crucial event in determining the final tumorigenic response; 10 days post MNU administration (Grubbs et al., 1986) or 6 days after DMBA administration reduces considerably tumour incidence, but no reduction occurs when mating is delayed 3 weeks (Moore et al., 1981) . In 3-MC treated rats the reduction is not so dramatic when mating occurs between 5 and 10 days post-carcinogen administration (Dao et al., 1960) . We still find protection when hCG is administered 21 days post-carcinogen treatment. These findings support the hypothesis that a placental hormone is able to modulate the initiated cell, thus blocking the progression of the neoplastic process.
The protective effect of hCG treatment prior to carcinogen administration is mediated through induction of gland differentiation, reduction in the proliferative activity of the mammary epithelium, reduction in binding of carcinogen to DNA and increasing DNA repair capabilities of the mammary epithelium (Russo, 1983; Russo et al., 1987a; Tay et al., 1985) . When given to young virgin rats, DMBA affects the highly proliferating epithelium of terminal end buds (TEBs). Cells affected by the carcinogen become transformed, developing intraductal proliferations (IDPs); by 21 days postcarcinogen administration, time at which hCG treatment was started, only a small number of IDPs had developed (Russo et al., 1977 (Russo et al., , 1982 . It remains to be clarified whether HCG administration acts by inhibiting cell proliferation and inducing differentiation in IDPs already present, as well as in those TEBs not expressing transformation yet. Although there is scanty information on the direct effect of hCG on the mammary gland, in vitro data indicate that hCG inhibits proliferative activity of the mammary epithelium (Moviglia et al., 1984; Russo et al., 1985) . Although hCG has been associated with tumorigenesis, since it is secreted by numerous trophoblastic and non-trophoblastic neoplasms (Asa et al., 1984; Chou et al., 1978) , it is not known at the present time what is the mechanism whereby hCG significantly decreases overall tumour incidence and tumour burden. Its effect has been reported variously to be that of an immunosuppressive agent (Contractor et al., 1973) , a mitogenic agent, a local growth factor (Melmed et al., 1983) , or an activator of c-myc and c-fos oncogenes, which in turn are important in the regulation of cell differentiation and proliferation (Cochran et al., 1984; Czerwiec et al., 1989) . Exogenous administration of hCG affects multiple endocrine organs; when given to rats in dioestrus it increases the plasma concentration of pituitary follicle-stimulating and luteinising hormones prior to induction of premature ovulation (Kimura et al., 1983; Segal, 1980; Uilenbrock et al., 1985) . It increases oestradiol concentrations in immature female rats which is associated with increased aromatase activity and is preceded by decreased 5-alpha-reductase activity (Uilenbrock et al., 1985) . Therefore, it is possible to postulate that the main effect of hCG on the mammary gland is mediated through stimulation of production of ovarian oestrogens and progesterone which in turn play an important role in tumour growth (Dao et al., 1959 (Dao et al., , 1960 Grubbs et al., 1983b Grubbs et al., , 1986 Huggins et al., 1961 Huggins et al., , 1962 McCormick et al., 1965 McCormick et al., , 1973 Welsch, 1985) .
Even though the mechanism of action of hCG remains to be explored, our results indicate that hCG in adequate doses may be a suitable hormone in breast cancer prevention and tumour progression after carcinogenic initiation. This knowledge eliminates the uncertainty of whether hCG treatment stimulates a process that had been already initiated at the time of hormonal treatment.
